SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
RNAi
An SI Board Since May 2003
Posts SubjectMarks Bans
671 52 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
171Vancouver and Berlin, 8 February, 2004 atugen AG, The Gene Silencing Company™, htuck-2/19/2004
170Study in Retina Demonstrates Acuity's siRNA Drug Inhibits Both Blood Vessel Thomas-2/18/2004
169Sirna (RNAI) 13-d filing today shows that Lilly does not own any Sirna stock. TThomas-2/17/2004
168The only publicly held reagent plays I know of are not even remotely pure. QGENtuck-2/17/2004
167Thanks, Tuck. Appreciate the link to the Dharmacon munch. What other reagent sThomas-2/17/2004
166[Review of Imgenex' GeneSupressor Kit] biocompare.com Cheers, Tucktuck-2/16/2004
165At the risk of repeating myself, I think first generation molecules will have prtuck-2/12/2004
164Hi Tuck, Well, *that* sounds like bad news for siRNA based therapeutics. . . ThThomas-2/11/2004
163Sirna Therapeutics Reports Year-End and Fourth Quarter Financial Results ThursdSemiBull-2/9/2004
162{Off target effects update] >>Published online before print February 9, 2tuck-2/9/2004
161[Off-target effects update] >>J Biol Chem. 2003 Nov 7;278(45):44312-9. tuck-2/4/2004
160[Inducible, reversible, and stable RNA interference in mammalian cells ] Interetuck-2/4/2004
159Compugen results (my emphasis added): TEL AVIV, Israel--(BUSINESS WIRE)--Feb. 4nigel bates-2/4/2004
158LAFAYETTE, Colo., Feb. 2 /PRNewswire/ -- Dharmacon, Inc., the leading global supnigel bates-2/2/2004
157>>BOTHELL, Wash., Feb. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical tuck-2/2/2004
156WUWT, Semi, Tuck, nigel, et al. Don't forget this is the same Lilly that wasThomas-1/28/2004
155I have a position as of today, so will be watching closely. Should have waited WhatsUpWithThat-1/27/2004
154<I>Market seems interested but not blown away??</I> Also a down marSemiBull-1/27/2004
153Well, it's only a research collaboration. Still, at least it means they are nigel bates-1/27/2004
152Market seems interested but not blown away?? Cheers WUWTWhatsUpWithThat-1/27/2004
151Sirna Therapeutics Announces RNAi Oncology Research Collaboration With Lilly Tuenigel bates-1/27/2004
150Alnylam Licenses Intellectual Property from Cold Spring Harbor Laboratory Thursdnigel bates-1/22/2004
149PLOS overview of the potential for RNAi therapeutics - plosbiology.org - whicnigel bates-1/21/2004
148This (Santaris) looks of some interest. Isis and Novo have stakes - santaris.cnigel bates-1/17/2004
147Press Release Source: Stanford University Medical Center Gene-Disabling Technikeokalani'nui-1/13/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News